We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmacopeia, an innovator in the discovery and development of novel small molecule therapeutics, announced today the formation of a drug discovery, development and commercialization alliance with Cephalon, Inc., a leading global biopharmaceutical company.
Phosphagenics Limited, the Australian Stock Exchange and the London Stock Exchange's Alternative Investment Market listed pharmaceutical and nutraceutical company, today announced that it has commenced the building of a production plant in Melbourne.
The U.S. FDA has given final approval to Israel-based Teva Pharmaceutical's abbreviated new drug application (ANDA) for the generic version of Forest Laboratories' Lexapro (escitalopram oxalate) tablets.
Auxilium Pharmaceuticals, headquartered in Malvern, Pa., has reported that Health Canada's Therapeutic Products Directorate has granted marketing approval for Testim, the company's topical testosterone gel for the treatment of hypogonadism (low testosterone).
British drugmaker SkyePharma has entered into an agreement with First Horizon Pharmaceutical to develop a controlled-release version of Sular (nisoldipine), an antihypertensive that is First Horizon's largest product.
India-based Peplin has launched a pilot Phase II clinical trial of its proprietary product, PEP005 Topical for the treatment of cutaneous squamous cell carcinoma in situ (SCCIS), in Australia, the company reported.
Urigen Holdings Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications and Kalium Inc., a California-based boutique drug development company, today announced that Urigen has licensed Kalium's patents and technology for the use of suppositories to deliver drug therapies to treat diseases of the genitourinary tract.
City-based Panacea Biotec on Monday said that it was in talks with three companies in Brazil for a marketing and distribution tie-up for immunosuppressive agent Cyclosporin, even as it intensifies its inorganic growth strategy for the US, Euro pe and Latin American markets.
Cellexus Biosystems PLC of Cambridgeshire, UK, has achieved a significant milestone when it unveiled its products to researchers attending the internationally renowned SCIpharm 2006 conference in Edinburgh this week.